Clinical Trial Search

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Number of Subjects With Study Related Adverse Events. — 59 Participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Complete Remission — 10 participants

Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants

Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability

Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability

Primary: Disease Free Survival — 1.7 years

Primary: Death Within 8 Weeks of the Study Cell Infusion Thought to be Definitely or Probably Related to Chimeric Antigen Receptor (CAR) T Cell Therapy — 0; 0; 1; 0 Participants

Primary: Engraftment — 15; 15 days

Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants

Primary: Complete Response Rate — 89 percentage of patients

Primary: Continuous Complete Remission at 1 Year — 21 participants

Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…

Primary: Incident Infection Rate in Participants During the First Year Post-acute Lymphoblastic Leukemia Therapy — 3.60 Events per person-year

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg

Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability

Primary: Number of Participants With Complete Remission (CR) — 68 Participants

Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants

Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants